Sinopharm Group Co released its earnings results on Aug 22, 2025. The company reported $0.765 earnings per share for the quarter, beating the consensus estimate of N/A by $0.765.

Is Sinopharm Group Co overvalued?

According to Wall Street analysts Sinopharm Group Co’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Sinopharm Group Co pay dividends?

Sinopharm Group Co pays a Annually dividend of $0.471 which represents an annual dividend yield of 4.01%. See more information on Sinopharm Group Co dividends here

What is Sinopharm Group Co’s EPS estimate?

Sinopharm Group Co’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Sinopharm Group Co have?

Sinopharm Group Co has 268,362,150 shares outstanding.

What happened to Sinopharm Group Co’s price movement after its last earnings report?

Sinopharm Group Co reported an EPS of $0.765 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.715%.

Which hedge fund is a major shareholder of Sinopharm Group Co?

Currently, no hedge funds are holding shares in SHTDY

Sinopharm Group Co Stock Smart Score

Underperform

Fundamentals

Return on Equity

8.74%

Trailing 12-Months

Asset Growth

-0.78%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Sinopharm Group Co

Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail drug stores, and clinics. This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. The Medical Devices segment distributes medical devices. The Retail Pharmacy segment operates and franchises a network of retail drug stores. As of December 31, 2021, this segment had 10,259 retail pharmacies. The Other Business segment engages in the production and sale of pharmaceutical products, chemical reagents, and laboratory supplies. The company also rents and manages properties; distributes medical instruments, Chinese herbal medicines, antibiotics, and biological products; and offers information technology development and medicine consultation, investment, goods and technology import and export, business consultation, health consultation, medical consultation, market information consultation and investigation, and convention and exhibition services. In addition, it manages medical project investment, consulting, and technology training activities. Sinopharm Group Co. Ltd. has a strategic partnership with I-Mab to enhance its commercial capabilities and commercialization transformation. The company was founded in 2003 and is headquartered in Shanghai, the People's Republic of China. Sinopharm Group Co. Ltd. is a subsidiary of Sinopharm Industrial Investment Co., Ltd.